149 related articles for article (PubMed ID: 21918608)
21. SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.
Alachkar H; Santhanam R; Maharry K; Metzeler KH; Huang X; Kohlschmidt J; Mendler JH; Benito JM; Hickey C; Neviani P; Dorrance AM; Anghelina M; Khalife J; Tarighat SS; Volinia S; Whitman SP; Paschka P; Hoellerbauer P; Wu YZ; Han L; Bolon BN; Blum W; Mrózek K; Carroll AJ; Perrotti D; Andreeff M; Caligiuri MA; Konopleva M; Garzon R; Bloomfield CD; Marcucci G
J Clin Invest; 2014 Apr; 124(4):1512-24. PubMed ID: 24590286
[TBL] [Abstract][Full Text] [Related]
22. Requirement of apoptotic protease-activating factor-1 for bortezomib-induced apoptosis but not for Fas-mediated apoptosis in human leukemic cells.
Ottosson-Wadlund A; Ceder R; Preta G; Pokrovskaja K; Grafström RC; Heyman M; Söderhäll S; Grandér D; Hedenfalk I; Robertson JD; Fadeel B
Mol Pharmacol; 2013 Jan; 83(1):245-55. PubMed ID: 23093495
[TBL] [Abstract][Full Text] [Related]
23. Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells.
Iskandarani A; Bhat AA; Siveen KS; Prabhu KS; Kuttikrishnan S; Khan MA; Krishnankutty R; Kulinski M; Nasr RR; Mohammad RM; Uddin S
J Transl Med; 2016 Mar; 14():69. PubMed ID: 26956626
[TBL] [Abstract][Full Text] [Related]
24. Characterization of bortezomib-adapted I-45 mesothelioma cells.
Zhang L; Littlejohn JE; Cui Y; Cao X; Peddaboina C; Smythe WR
Mol Cancer; 2010 May; 9():110. PubMed ID: 20482802
[TBL] [Abstract][Full Text] [Related]
25. SRT1720 induces SIRT1-independent cell death in adult T-cell leukemia/lymphoma.
Kozako T; Kato N; Ohsugi T; Uchida YI; Yoshimitsu M; Ishitsuka K; Higaki Y; Sato H; Aikawa A; Honda SI
FEBS J; 2022 Jun; 289(12):3477-3488. PubMed ID: 35029032
[TBL] [Abstract][Full Text] [Related]
26. YM155 suppresses cell proliferation and induces cell death in human adult T-cell leukemia/lymphoma cells.
Sasaki R; Ito S; Asahi M; Ishida Y
Leuk Res; 2015 Dec; 39(12):1473-9. PubMed ID: 26547260
[TBL] [Abstract][Full Text] [Related]
27. Target mechanism-based whole-cell screening identifies bortezomib as an inhibitor of caseinolytic protease in mycobacteria.
Moreira W; Ngan GJ; Low JL; Poulsen A; Chia BC; Ang MJ; Yap A; Fulwood J; Lakshmanan U; Lim J; Khoo AY; Flotow H; Hill J; Raju RM; Rubin EJ; Dick T
mBio; 2015 May; 6(3):e00253-15. PubMed ID: 25944857
[TBL] [Abstract][Full Text] [Related]
28. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies.
Zhao X; Qiu W; Kung J; Zhao X; Peng X; Yegappan M; Yen-Lieberman B; Hsi ED
Leuk Res; 2008 Feb; 32(2):275-85. PubMed ID: 17659339
[TBL] [Abstract][Full Text] [Related]
29. Secreted Protein Acidic and Rich in Cysteine (
Ghanemi A; Yoshioka M; St-Amand J
Diseases; 2023 Feb; 11(1):. PubMed ID: 36810547
[TBL] [Abstract][Full Text] [Related]
30. Treating MCF7 breast cancer cell with proteasome inhibitor Bortezomib restores apoptotic factors and sensitizes cell to Docetaxel.
Mehdizadeh K; Ataei F; Hosseinkhani S
Med Oncol; 2021 Apr; 38(6):64. PubMed ID: 33904968
[TBL] [Abstract][Full Text] [Related]
31. SPARC ectopic overexpression inhibits growth and promotes programmed cell death in acute myeloid leukemia transformed from myelodysplastic syndrome cells, alone and in combination with Ara-C treatment.
Nian Q; Chi J; Xiao Q; Wei C; Costeas P; Yang Z; Liu L; Wang L
Oncol Rep; 2015 Sep; 34(3):1406-14. PubMed ID: 26165695
[TBL] [Abstract][Full Text] [Related]
32. Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells.
Fuchs O; Provaznikova D; Marinov I; Kuzelova K; Spicka I
Cardiovasc Hematol Disord Drug Targets; 2009 Mar; 9(1):62-77. PubMed ID: 19275578
[TBL] [Abstract][Full Text] [Related]
33. SPARC is a key mediator of TGF-β-induced renal cancer metastasis.
Bao JM; Dang Q; Lin CJ; Lo UG; Feldkoren B; Dang A; Hernandez E; Li F; Panwar V; Lee CF; Cen JJ; Guan B; Margulis V; Kapur P; Brekken RA; Luo JH; Hsieh JT; Tan WL
J Cell Physiol; 2021 Mar; 236(3):1926-1938. PubMed ID: 32780451
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of HSP27 alone or in combination with pAKT inhibition as therapeutic approaches to target SPARC-induced glioma cell survival.
Schultz CR; Golembieski WA; King DA; Brown SL; Brodie C; Rempel SA
Mol Cancer; 2012 Apr; 11():20. PubMed ID: 22480225
[TBL] [Abstract][Full Text] [Related]
35. TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response.
Nowis D; McConnell EJ; Dierlam L; Palamarchuk A; Lass A; Wójcik C
Int J Cancer; 2007 Jul; 121(2):431-41. PubMed ID: 17373661
[TBL] [Abstract][Full Text] [Related]
36. Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells.
Liu CY; Shiau CW; Kuo HY; Huang HP; Chen MH; Tzeng CH; Chen KF
Haematologica; 2013 May; 98(5):729-38. PubMed ID: 22983581
[TBL] [Abstract][Full Text] [Related]
37. Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta.
Yan H; Wang YC; Li D; Wang Y; Liu W; Wu YL; Chen GQ
Leukemia; 2007 Jul; 21(7):1488-95. PubMed ID: 17495969
[TBL] [Abstract][Full Text] [Related]
38. WRN-targeted therapy using inhibitors NSC 19630 and NSC 617145 induce apoptosis in HTLV-1-transformed adult T-cell leukemia cells.
Moles R; Bai XT; Chaib-Mezrag H; Nicot C
J Hematol Oncol; 2016 Nov; 9(1):121. PubMed ID: 27829440
[TBL] [Abstract][Full Text] [Related]
39. cDNA array analysis of SPARC-modulated changes in glioma gene expression.
Golembieski WA; Rempel SA
J Neurooncol; 2002 Dec; 60(3):213-26. PubMed ID: 12510773
[TBL] [Abstract][Full Text] [Related]
40. Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells.
Periyasamy-Thandavan S; Jackson WH; Samaddar JS; Erickson B; Barrett JR; Raney L; Gopal E; Ganapathy V; Hill WD; Bhalla KN; Schoenlein PV
Autophagy; 2010 Jan; 6(1):19-35. PubMed ID: 20110775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
